Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A new line of treatment discovered for acute lymphoblastic leucemia

09.02.2007
A study undertaken by a group of Spanish scientists, amongst which were members of the University Clinic of the University of Navarra and the Centre for Applied Medical Research (CIMA) of the same university, have recently discovered a new line of treatment for patients with acute lymphoblastic leucemia. The conclusions of the research have been published in the official journal, Blood, of the American Haematology Association.

It should be noted that acute lymphoblastic leucemia is the most common oncological disease amongst children. This is why the application of this discovery could be highly beneficial for a special group of patients with this disorder – those who show the cellular control pathway known as WNT as altered, - and whose prognosis of this tumour disease is serious.

The WNT pathway is the device that a normal cell needs to activate in order to initiate a process of cell growth and which, once realised, should deactivate itself. However, it has been shown that, in those groups of acute lymphoblastic leucemia patients with the worst prognoses, this cell control pathway appears to be constantly activated. This phenomenon occurs because the mechanisms controlling this pathway have been silenced due to a process which affects gene transcription and known as metilation. The WNT pathway activated in an ongoing manner gives rise to the expression of specific genes whose function is to activate the growth of tumour cells.

Administration of new medicinal drugs

... more about:
»Wnt »acute »leucemia »lymphoblastic

The study has shown, with in vitro trials, that administering a type of medication which impedes this process of metilation or which inactivates the WNT pathway, results in the normalisation of this cell control pathway and, so, impedes the development of tumour cells, inducing the death of the leucemia cells. In this way, this group of medicines will help to enhance chemotherapy results and raise the rates of survival amongst these patients.

The discovery provides a rational basis for being able to use a series of drugs for this disease - such as quercetine (which produces a programmed death of acute lymphoblastic leucemia cells) or Decitabine, medication, already used with other kinds of pathologies.

The next stage in the research will involve the application of trials, based on these studies, in rats, in order to determine which of these drugs are, in fact, efficacious. Once this has been determined, clinical trials with patients will be proposed.

If the results of the application of this research prove to be a success, one consequence may be that the classification of patients with acute lymphoblastic leucemia can be carried out on the basis of the state of activation of the WNT pathway, as this is considered to be a risk factor in the worsening of the disease and in its possible cure.

Irati Kortabitarte | alfa
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Gelaxka=1_1&hizk=I&Berri_Kod=1182

Further reports about: Wnt acute leucemia lymphoblastic

More articles from Life Sciences:

nachricht Closing the carbon loop
08.12.2016 | University of Pittsburgh

nachricht Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>